Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(15 sites)

China

Peking University First Hospital (First Clinical Medical School of Peking University), Beijing, Beijing Municipality

Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality

Fujian Cancer Hospital, Fuzhou, Fujian

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei

Hunan Cancer Hospital, Changsha, Hunan

The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu

The First Hospital of China Medical University, Shenyang, Liaoning

Qilu Hospital of Shandong University, Jinan, Shandong

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality

West China Hospital, Sichuan University, Chengdu, Sichuan

The Second Hospital of Tianjin Medical University, Tianjin, Tianjin Municipality

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang